Tharimmune to Present at the Microcap Conference 2025

Rhea-AI Summary

Tharimmune (Nasdaq: THAR), a clinical-stage biotechnology company focused on immunology and inflammation therapies, has announced its participation in The Microcap Conference 2025. The event will take place from January 28-30, 2025, at the Borgata Hotel Casino & Spa in Atlantic City, New Jersey.

The company's management team will deliver a corporate presentation on Thursday, January 30, 2025, at 10:00 AM Eastern Time in Studio 4. During the conference, they will engage in one-on-one meetings with institutional and individual investors to discuss recent developments, growth strategy, and investment opportunities. Interested investors can register for the conference through the provided link.

News Market Reaction

-2.90%

1 alert

-2.90% News Effect

On the day this news was published, THAR declined 2.90%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

BRIDGEWATER, NJ / ACCESS Newswire / January 27, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced its participation in The Microcap Conference 2025 being held January 28-30, 2025, in Atlantic City, N.J.

Management will deliver a corporate presentation and engage in one-on-one meetings with institutional and individual investors to discuss the company's recent developments, growth strategy, and investment opportunities.

Event: The Microcap Conference 2025
Location: Studio 4, Borgata Hotel Casino & Spa
Date: Thursday January 30, 2025
Time: 10:00 AM Eastern Time

Investors interested in meeting with management can register for the conference here.

About Tharimmune

Tharimmune, Inc. is a clinical-stage biotechnology company developing a diverse portfolio of therapeutic candidates in immunology, inflammation and oncology. Its lead clinical asset, TH104, aims to suppress chronic pruritus associated with primary biliary cholangitis (PBC), a rare autoimmune liver disease with no known cure. The expanded pipeline includes TH023, an oral TNF-alpha inhibitor, offering a new approach to treating autoimmune diseases. Tharimmune is also advancing early-stage multi-specific biologics targeting unique epitopes against multiple solid tumors. The company has a license agreement with OmniAb, Inc. to access their antibody discovery technology for targeting specified disease markers. For more information, please visit: www.tharimmune.com.

Contacts

Tharimmune, Inc.
ir@tharimmune.com

Alliance Advisors IR
Tirth T. Patel
tpatel@allianceadvisors.com
212-201-6614

Contact Information

Tirth Patel
Alliance Advisors IR
tpatel@allianceadvisors.com
1-212-201-6614

SOURCE: Tharimmune Inc.

View the original press release on ACCESS Newswire

FAQ

When and where is Tharimmune (THAR) presenting at The Microcap Conference 2025?

Tharimmune will present on Thursday, January 30, 2025, at 10:00 AM Eastern Time in Studio 4 at the Borgata Hotel Casino & Spa in Atlantic City, New Jersey.

What will Tharimmune (THAR) discuss at The Microcap Conference 2025?

Management will discuss the company's recent developments, growth strategy, and investment opportunities during their corporate presentation and one-on-one meetings with investors.

How can investors meet with Tharimmune (THAR) management at The Microcap Conference 2025?

Investors interested in meeting with management can register for the conference through the provided registration link.

What is the duration of The Microcap Conference 2025 where Tharimmune (THAR) is presenting?

The Microcap Conference 2025 runs from January 28-30, 2025.